Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, ...

Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.

Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

Life expectancy in the United States is worse than in many other countries and declined from 1990 to 2021, data suggest.

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

The risk of melanoma-related death is greater for patients with primary tumors that are 0.8-1.0 mm thick than for patients with thinner tumors, data suggest.

Rucaparib Maintenance Improves Long-Term Outcomes in Ovarian Cancer Rucaparib maintenance after first-line chemotherapy and ...

Though lung cancer survival rates are improving, lung cancer is still the leading cause of cancer deaths in the US.

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

Pirtobrutinib improved outcomes over investigator’s choice of treatment in patients with CLL/SLL previously treated with a cBTKi.